COVID-19 Critical Intelligence Unit

Daily evidence digest

17 March 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Molnupiravir, mechanical thrombectomy for acute ischaemic stroke in COVID-19 patients, acute COVID-19 severity and mental health trajectories

Peer reviewed journals featured:

- A systematic review on molnupiravir for treating COVID-19 patients <u>here</u>
- A cluster randomised trial of a social media campaign to increase COVID-19 testing in migrant groups in Norway <u>here</u>
- Observational studies on:
 - o Mechanical thrombectomy for acute ischaemic stroke in COVID-19 patients here
 - Acute COVID-19 severity and mental health morbidity trajectories in 6 countries here
 - Prognostic value of National Early Warning Scores (NEWS2) and component physiology in COVID-19 inpatients <u>here</u>
 - Vaccine hesitancy and monetary incentives <u>here</u>
 - o Comparison of Delta vs Omicron infected patients in Paris emergency departments here
 - o RT-PCR and BinaxNOW rapid antigen tests during the Omicron surge here
 - A crisis scoring system for resource prioritisation, and estimated excess mortality by race, ethnicity and social vulnerability in the US here and associated commentary here
 - SARS-CoV-2 burden and transmission in a rural and an urban setting in South Africa here and associated commentary here
- Commentary on:
 - The NHS recovery from COVID-19 and learning from other countries here
 - o The UK's "living with COVID" plan here

Pre-peer review articles featured:

- Post-acute sequelae 6-12 months after SARS-CoV-2 infection here
- Omicron spike gene mutations and inter-variant recombination events here
- Omicron variant and new mutations in New Zealand and Hong Kong here



Guidance and reports

- The World Health Organization published an update of its COVID-19 vaccine tracker <u>here</u>, operational report <u>here</u> COVID-19 epidemiological report <u>here</u> and guidance on the use of:
 - o AstraZeneca (Vaxzevria™, SII COVISHIELD™) COVID-19 vaccine here and here
 - o Bharat Biotech BBV152 COVAXIN® COVID-19 vaccine here and here
 - o Sinopharm BIBP COVID-19 vaccine (BIBP-CorV, Covilo) here and here
 - Sinovac CoronaVac COVID-19 vaccine <u>here</u> and <u>here</u>

News and blogs

- Surge of HIV, tuberculosis and COVID-19 feared amid war in Ukraine here
- Russian COVID-19 vaccine in jeopardy after Ukraine invasion <u>here</u>
- Sashay the virus away here

<u>Click here</u> to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on <u>COVID-19 transmission</u>, SARS-CoV-2 <u>vaccines</u>, and <u>variants</u> of concern, <u>post-acute sequelae of COVID-19 (PASC)</u>, <u>surgery and COVID-19</u>, <u>rapid testing</u> and <u>risk mitigation strategies</u>.



The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.